

## AMENDMENT TO THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) An isolated polypeptide, derivative or analogue thereof, comprising a tandem repeat of apolipoprotein B, wherein the isolated polypeptide, derivative or analogue thereof is according to formula I:

abcRKRxyzab'c'RKRx'y'z' (I)

wherein

a and a' are each independently selected from the group consisting of a positively charged residue, which may be Arginine (R), Lysine (K) or Histidine (H), Leucine (L), Tryptophan (W), and deleted;

b and b' are each independently selected from the group consisting of Leucine (L), Arginine (R), Lysine (K), and deleted;

c and c' are each independently selected from the group consisting of Threonine (T), Tryptophan (W), and a positively charged residue, which may be Arginine (R), Lysine (K) or Histidine (H);

x and x' are each independently selected from the group consisting of Glycine (G), Tryptophan (W), Leucine (L), and a positively charged residue, which may be Arginine (R), Lysine (K) or Histidine (H);

y and y' are each independently selected from the group consisting of Leucine (L), a positively charged residue, which may be Arginine (R), Lysine (K) or Histidine (H), and deleted; and

z and z' are each independently selected from the group consisting of a positively charged residue, which may be Arginine (R), Lysine (K) or Histidine (H), Leucine, and deleted,

or a truncation thereof comprising the tandem repeat of apolipoprotein B, characterised in that the tandem repeat or truncation thereof comprising the tandem repeat of apolipoprotein B is obtained from a heparin sulphate proteoglycan (HSPG) receptor binding region of apolipoprotein B.

2. (Previously Presented) The isolated polypeptide, derivative or analogue thereof according to claim 1, wherein the polypeptide, derivative or analogue thereof comprises a tandem repeat which is obtained from an apolipoprotein B LDL receptor binding domain cluster B.
3. (Currently Amended) The isolated polypeptide, derivative or analogue thereof according to claim 1 comprising a tandem repeat of human apolipoprotein B<sub>(3359-3367)</sub> having amino acid sequence RLTRKRGLK (SEQ ID ~~No.1~~ NO:1), or a truncation thereof comprising the tandem repeat.
4. (Currently Amended) The isolated polypeptide, derivative or analogue thereof according to claim 1 comprising a tandem repeat of the amino acid sequence of SEQ ID ~~No.1~~ NO:1.
5. (Previously Presented) The isolated polypeptide, derivative or analogue thereof according to claim 3, wherein at least one of the first, second, third, seventh, eighth, ninth, tenth, eleventh, twelfth, sixteenth, seventeenth or eighteenth residues is substituted or deleted.

Claim 6 (Canceled).

7. (Currently Amended) The isolated polypeptide, derivative or analogue thereof according to claim 1 comprising the amino acid sequence:  
 LRTRKRGRKLTRKRGRK (SEQ ID NO:48 ~~No.48~~);  
 RTRKRGRKRTRKRGRK (SEQ ID NO:3 ~~No.3~~);  
 RTRKRGRTRKRGR (SEQ ID NO:4 ~~No.4~~);  
 LRKRKRLLRKRKRL (SEQ ID NO:5 ~~No.5~~);  
 LRKRKRLRKLKRKRLRK (SEQ ID NO:6 ~~No.6~~);  
 WRWRKRWKWRWRKRWK (SEQ ID NO:7 ~~No.7~~);  
 RRWRKRWKWRWRKRWK (SEQ ID NO:34 ~~No.34~~);  
 KRWRKRWKWRWRKRWK (SEQ ID NO:35 ~~No.35~~);  
 LRWRKRWKWRWRKRWK (SEQ ID NO:36 ~~No.36~~);

HRWRKRWRKWRWRKRWRK (SEQ ID NO:37 ~~No.37~~);  
RWRKRWRKWRWRKRWRK (SEQ ID NO:38 ~~No.38~~);  
RRWRKRWRKRRWRKRWRK (SEQ ID NO:39 ~~No.39~~);  
KRWRKRWRKKRWRKRWRK (SEQ ID NO:40 ~~No.40~~);  
LRWRKRWRKLRWRKRWRK (SEQ ID NO:41 ~~No.41~~);  
HRWRKRWRKHRWRKRWRK (SEQ ID NO:42 ~~No.42~~);  
RWRKRWRKRWRKRWRK (SEQ ID NO:43 ~~No.43~~);  
RWRKRGRKRWRKRGRK (SEQ ID NO:44 ~~No.44~~);  
RTRKRWRKRTRKRGRK (SEQ ID NO:45 ~~No.45~~);  
RWRKRWRKRWRKRWRK (SEQ ID NO:46 ~~No.46~~); or  
RWRKRWRWRKRWRWRKRW (SEQ ID NO:47 ~~No.47~~).

8. (Previously Presented) A composition, comprising the isolated polypeptide, derivative or analogue thereof according to claim 1.

Claim 9 (Canceled).

10. (Withdrawn) A method of preventing and/or treating a viral infection, comprising administering to a subject in need of treatment a therapeutically effective amount of the polypeptide, derivative or analogue according to claim 1.
11. (Withdrawn) An agent adapted to increase the biological activity of the polypeptide, derivative or analogue according to claim 1.

Claim 12 (Canceled).

13. (Withdrawn) A nucleic acid sequence encoding the polypeptide, derivative or analogue according to claim 1.
14. (Withdrawn) A composition, comprising the nucleic acid according to claim 13.

Claim 15 (Canceled).

16. (Withdrawn-Currently Amended) The nucleic acid according to claim 13, wherein the nucleic acid comprises a nucleotide sequence as set out as SEQ ID ~~No.8~~ NO:8 (apoB3359-3367), SEQ ID ~~No.9~~ NO:9 (GIN 16), SEQ ID ~~No.10~~ NO:10 (GIN 35), SEQ ID ~~No.11~~ NO:11 (GIN 36), SEQ ID ~~No.12~~ NO:12 (GIN 37), SEQ ID ~~No.13~~ NO:13 (GIN 38), or SEQ ID ~~No.14~~ NO:14 (GIN 33).
17. (Withdrawn) A method of preventing and/or treating a viral infection, comprising administering to a subject in need of treatment a therapeutically effective amount of the nucleic acid according to claim 13.
18. (Previously Presented) The isolated polypeptide, derivative or analogue thereof according to claim 4, wherein at least one of the first, second, third, seventh, eighth, ninth, tenth, eleventh, twelfth, sixteenth, seventeenth or eighteenth residues is substituted or deleted.